1. Industry

Discuss in my forum

New Drugs Approved in 2011 (continued) - HAE, Clotting Disorder, Scorpion Stings

By , About.com Guide

New Drugs Approved in 2011 (continued) - HAE, Clotting Disorder, Scorpion Stings

Corifact, developed for the prevention of bleeding in people with congenital Factor XIII deficiency, a rare genetic defect, was approved in 2011.

CSL Behring

Hereditary Angioedema (HAE) Treatment

  • Firmware (icatibant) to treat acute attacks of hereditary angioedema (HAE), Shire

HAE is a rare disease caused by low levels or improper functioning of C1 inhibitor protein which is involved in the regulation of immune system and blood clotting pathways.

Clotting Disorder Prevention

  • Corifact (Factor XIII Concentrate[Human]) for the prevention of bleeding in people with congenital Factor XIII deficiency, rare genetic defect, CSL Behring

Corifact is the first specific treatment approved in the U.S. to prevent bleeding in people with congenital Factor XIII deficiency, according to the FDA.

Scorpion Stings Treatment

  • Anascorp (Centruroides [Scorpion] Immune F(ab')2 [Equine]) to treat clinical signs of scorpion envenomation. Rare Disease Therapeutics Inc.

Anascorp, a designated

  1. About.com
  2. Industry
  3. Pharma
  4. FDA Approval
  5. New Drugs Approved in 2011 (continued) - Hereditary Angioedema(HAE), Clotting Disorder, Scorpion Stings

©2013 About.com. All rights reserved.